

Rhythm Biosciences Limited
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	Rhythm Biosciences Limited
ABN:	59 619 459 335
Reporting period:	For the year ended 30 June 2025
Previous period:	For the year ended 30 June 2024

2. Results for announcement to the market

		2025	2024
		\$	\$
Other income from ordinary activities	Up 91% to	3,326,241	1,742,426
Loss from ordinary activities after tax attributable to the owners of Rhythm Biosciences Limited	Down 44% to	(3,829,371)	(6,856,761)
Comprehensive loss for the year attributable to the owners of Rhythm Biosciences Limited	Down 44% to	(3,832,300)	(6,856,761)

Dividends

There were no dividends paid, recommended or declared during the financial year.

Comments

The loss for the consolidated entity after providing for income tax was \$3,829,371. Comments on activities during the year are included in the Financial Report.

3. Net tangible assets

	Reporting period	Previous period
	Cents	Cents
Net tangible assets per ordinary security	<u>(0.10)</u>	<u>0.14</u>

4. Control gained over entities

RHY GeneType Pty Ltd, was incorporated in Australia on 18 December 2024 as a 100% owned subsidiary.

5. Loss of control over entities

Not applicable.

6. Details of associates and joint venture entities

Not applicable.

7. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unqualified opinion has been issued.

8. Attachments

Details of attachments (if any):

The Annual Report of Rhythm Biosciences Limited for the year ended 30 June 2025 is attached.

9. Signed



Otto Buttula
Non-Executive Chairman

Date: 29 August 2025